國投資本(600061.SH):擬對安信證券增資約79.44億元
格隆匯 8 月 5日丨國投資本(600061.SH)公佈,2020年8月5日,公司、上海毅勝投資有限公司(“毅勝投資”)、安信證券股份有限公司(“安信證券”)簽署《國投資本股份有限公司與上海毅勝投資有限公司關於安信證券股有限公司之增資協議》,公司及毅勝投資對安信證券增資金額合計約79.44億元,毅勝投資是公司全資子公司。
此次增資將主要用於安信證券信用交易業務、證券投資業務、信息系統建設、增資期貨公司及另類投資公司等,通過增加安信證券的資本金,補充其營運資金,優化業務結構,擴大業務規模,提升市場競爭力和抗風險能力。增資不會導致上市公司合併報表範圍發生變更,安信證券仍是公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.